Adalimumab for psoriasis: Practical experience in a U.K. tertiary referral centreCitation formats
Standard
Adalimumab for psoriasis: Practical experience in a U.K. tertiary referral centre. / Warren, R. B.; Brown, B. C.; Lavery, D.; Griffiths, C. E M.
In: British Journal of Dermatology, Vol. 163, No. 4, 10.2010, p. 859-862.Research output: Contribution to journal › Article
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Adalimumab for psoriasis: Practical experience in a U.K. tertiary referral centre
AU - Warren, R. B.
AU - Brown, B. C.
AU - Lavery, D.
AU - Griffiths, C. E M
PY - 2010/10
Y1 - 2010/10
N2 - SummaryBackground There are few reports of the practical use of adalimumab outside a clinical trial setting and, to our knowledge, none from the U.K. Objectives We assessed the efficacy and safety of adalimumab in a cohort of patients with severe psoriasis attending a tertiary dermatology referral centre in the U.K. Methods A retrospective case-note review was used to identify all patients initiated on adalimumab for psoriasis. Results Mean ± SD baseline Psoriasis Area and Severity Index (PASI) score was 24 ± 11 (range 9-54; n = 46). After 4 months' treatment with adalimumab, 64% (29/45) of patients had achieved PASI 75 (75% decrease from baseline) while 80% (36/45) of patients met National Institute for Health and Clinical Excellence (NICE) criteria for continuation of treatment. The therapy was well tolerated. Importantly, 68% (21/31) of patients who had previously received another tumour necrosis factor-α inhibitor met NICE criteria for continuation of treatment at 16 weeks. Conclusions In a cohort of U.K. patients with severe psoriasis, adalimumab has proved to be a significant addition to the expanding armamentarium of biologics for psoriasis. Pharmacovigilance, in the form of registries, is essential to assess the long-term safety of such drugs. © 2010 British Association of Dermatologists.
AB - SummaryBackground There are few reports of the practical use of adalimumab outside a clinical trial setting and, to our knowledge, none from the U.K. Objectives We assessed the efficacy and safety of adalimumab in a cohort of patients with severe psoriasis attending a tertiary dermatology referral centre in the U.K. Methods A retrospective case-note review was used to identify all patients initiated on adalimumab for psoriasis. Results Mean ± SD baseline Psoriasis Area and Severity Index (PASI) score was 24 ± 11 (range 9-54; n = 46). After 4 months' treatment with adalimumab, 64% (29/45) of patients had achieved PASI 75 (75% decrease from baseline) while 80% (36/45) of patients met National Institute for Health and Clinical Excellence (NICE) criteria for continuation of treatment. The therapy was well tolerated. Importantly, 68% (21/31) of patients who had previously received another tumour necrosis factor-α inhibitor met NICE criteria for continuation of treatment at 16 weeks. Conclusions In a cohort of U.K. patients with severe psoriasis, adalimumab has proved to be a significant addition to the expanding armamentarium of biologics for psoriasis. Pharmacovigilance, in the form of registries, is essential to assess the long-term safety of such drugs. © 2010 British Association of Dermatologists.
KW - adalimumab
KW - biological therapy
KW - psoriasis
U2 - 10.1111/j.1365-2133.2010.09986.x
DO - 10.1111/j.1365-2133.2010.09986.x
M3 - Article
VL - 163
SP - 859
EP - 862
JO - British Journal of Dermatology
JF - British Journal of Dermatology
SN - 0007-0963
IS - 4
ER -